ELSEVIER

Contents lists available at ScienceDirect

European Journal of Cancer

journal homepage: www.ejcancer.com

-

EJC -

LORIC

Corrigendum

Corrigendum to “Impact of EDP-M on survival of patients with metastatic adrenocortical carcinoma: A population-based study” [Eur J Cancer 196 (2024) 113424]

Check for updates

Pien Debets ª, Koen M.A. Dreijerink b,k, Anton F. Engelsman ”, Max Dahele d, Harm R. Haak e,f,g, Rebecca V. Steenaard e,f,j, Ellen Kapiteijn h, Eleonora Corssmit1, C. Willemien Menke-van der Houven van Oordta,k,

a Amsterdam UMC Location VU Medical Center, Department of Medical Oncology, Amsterdam, the Netherlands

b Amsterdam UMC Location VU Medical Center, Department of Endocrinology and Metabolism, Amsterdam, the Netherlands

” Amsterdam UMC Location VU Medical Center, Department of Surgery, Amsterdam, the Netherlands

d Amsterdam UMC Location VU Medical Center, Department of Radiation Oncology and Cancer Center Amsterdam, Amsterdam, the Netherlands

e Maxima Medical Center, Department of Internal Medicine, Eindhoven, the Netherlands

Maastricht University, CAPHRI School for Public Health and Primary Care, Ageing and Long-Term Care, Maastricht, the Netherlands

% Department of Internal Medicine, Division of General Internal Medicine, Maastricht University Medical Centre+, Maastricht, the Netherlands

h Leiden University Medical Center, Department of Medical Oncology, Leiden, the Netherlands

Leiden University Medical Center, Center of Endocrine Tumours, Division of Endocrinology, Department of Internal Medicine, Leiden, the Netherlands

¿ Netherlands Comprehensive Cancer Organization (IKNL), Utrecht, the Netherlands

k Cancer Center Amsterdam, the Netherlands

The authors regret to inform that we need to make a small correction regarding the number of patients with a hormone producing tumor in our recent publication. This change does not regard any of the primary outcomes of the study but we believe should be updated nonetheless.

The corrected numbers of patients with a hormone producing tumor are detailed below ( Tables 1 and 2).

The authors would like to apologise for any inconvenience caused.

DOI of original article: https://doi.org/10.1016/j.ejca.2023.113424.

* Corresponding author at: Amsterdam UMC Location VU Medical Center, Department of Medical Oncology, Amsterdam, the Netherlands. E-mail address: c.menke@amsterdamumc.nl (C. Willemien Menke-van der Houven van Oordt).

Table 1 Demographics and clinical characteristics of patients diagnosed with mACC in the Netherlands between 2005 and 2020.
Hormone productionTotal (N)Pre-2014Post 2014P-value
No23X ☒23
Yes52X ☒52x ☒
Table 2 Multivariate analysis of variables associated with survival of patients with mACC diagnosed from 2014 onwards.
Hormone productionMedian OS (months)Univariate HR (95 % CI)P- valueMultivariate HR (95 % CI)P- value
No12referencex ☒x ☒
Yes81.13 (0.64 - 2.0)0.680x ☒x ☒